This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HTR2B · Western blot design guide
HTR2B Western Blot Planning Guide
Plan a HTR2B Western blot around the catalog-observed 54.3 kDa band, image-backed PB9600 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
HTR2B Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 54.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Cervix | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 54.3 kDa |
| ⓘ | Localization | Cell membrane / Synapse, synaptosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Rat |
Section 1
Real Curated HTR2B Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Cervix |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9600 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected HTR2B Western Blot Band Size?
Use the product-observed 54.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 54.3 kDa | Matches the authoritative product WB observation. |
| 54.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected HTR2B appearancePlan around 54.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 54.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 54.3 kDa from UniProt P41595; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9600. |
| Situation | Likely cause | Next action |
|---|---|---|
| 54.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing HTR2B band
PB9600 · HTR2B
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for HTR2B Western blot
🧪Use Cervix as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Cervix (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for HTR2B
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
| Placenta | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced HTR2B Western Blot Tips
Deeper troubleshooting and optimisation questions for HTR2B, answered from its protein features.
Which band should guide the blot?
Use 54.3 kDa, the observation attached to the authoritative PB9600 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 54.3 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for HTR2B Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9600 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
HTR2B Western Blot Reagents
Human/Rat-reactive HTR2B Western blot reagents with authoritative product imagery.
Real WB data
Anti-5HT2B Receptor/HTR2B Antibody Picoband®
Cat # PB9600
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P41595
- Human Protein Atlas — HTR2B
- PB9600 product record
- PMC11000286 — SP1 transcriptionally activates HTR2B to aggravate traumatic spinal cord injury by shifting microglial M1/M2 polarization (Journal of orthopaedic surgery and research, 2024)
- PMC10321165 — Serotonin receptor subtype-2B signaling is associated with interleukin-18-induced cardiomyoblast hypertrophy in vitro (Asian biomedicine : research, reviews and news, 2022)
- PMC12362726 — Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity (Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025)
